Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Novel Patho-Seq Assay Discovered for the Detection of Bacteria
Pathogenomix Inc, discovered novel Patho-Seq assay. Patho-Seq uses Next Generation Sequencing for the rapid identifaction of bacteria presented in human sample through dangerous and life-threatening infections. Patho-Seq detects hundreds of clinically relevant bacteria collected from wide
Telisotuzumab Vedotin (Teliso-V) Developed for the Treatment of Non-Small Cell Lung Cancer
AbbVie developed Telisotuzumab Vedotin (Teliso-V) an investigational antibody-drug conjugate (ADC), to treat patients with non-small cell lung cancer (NSCLC). (Teliso-V) is used to treat patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) consisting
New Patritumab Deruxtecan (HER3-DXd) Discovered for the Treatment of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo discovered new patritumab deruxtecan to treat patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC). Patritumab deruxtecan (HER3-DXd), is the firt irst-in-class HER3 directed antibody drug conjugate (ADC), applicable with third-generation tyrosine kinase inhibitor
Novel ZetaMet™ Technology Discovered for Metastatic Bone Cancers
Zetagen Therapeutics, discovered novel ZetaMet™ technology for the treatment of metastatic bone cancers. This technology is the first to suspend cancer inhibit pain, and regenerate bone. ZetaMet™ technology was earlier known as ZetaFuse. It is a synthetic, small-molecule, inductive biologic technology introduced to target and resolve metastatic
Breakthrough Biology-Guided Radiotherapy* (BgRT) Discovered for the Treatment of Lung Tumors
RefleXion Medical, Inc discovered breakthrough biology-guided radiotherapy* (BgRT)for the treatment of lung cancer. Biology-guided radiotherapy(BgRT), the first and only technology has the ability to detect and treat the circulating tumours producing active emissions from each tumour.
Pear Therapeutics Developed reSET-A™ PDT Product Candidate for Alcohol Use Disorder (AUD)
Pear therapeutics developed new reSET-A™ PDT product candidate for the treatment of alcohol use disorder (AUD) PDTsare new therapeutic class designed with software to directly treat disease. Similar to traditional medicines, PDT’s are developed and tested
Susvimo™, Breakthrough Therapy Discovered for Wet Age-Related Macular Degeneration (nAMD)
Roche discovered breakthrough therapy Susvimo™ (ranibizumab injection) for the treatment of people with neovascular or ‘wet’ age-related macular degeneration (nAMD). Susvimoearlier known as port delivery system with ranibizumab is the first and only alternative treatment in 15 years which provides standard-of-care
Novel NonInvasive Sonic Beam Device Developed for Non-Invasive Liver Treatment
HistoSonics developed novel sonic beam therapy for the destruction of targeted liver tissue. The new targeted liver therapy helps in providing timely access to non-invasive liver treatment and destructs targeted liver tissue. This is the first automated external beam therapy which makes use of acoustic energy
New Exo-PDAC Assay Discovered for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC)
Biological Dynamics, Inc discovered new Exo-PDAC, liquid biopsy assay for the early detection of pancreatic ductal adenocarcinoma (PDAC) in high-risk adults. Globally, pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal forms of cancer.
Novel Repotrectinib Therapeutic Option Discovered for Advanced Solid Tumors
Turning Point Therapeutics, Inc discovered novel repotrectinib, a leading drug candidate for the treatment of patients with advanced solid tumors having an NTRK gene fusion. Repotrectinib is a therapeutic option for patients who have shown progress with 1 or 2 prior TRK TKIs after treatment, with or without prior chemotherapy
